SEC Charges Ipsen Worker for Insider Trading Tied to $247M Epizyme Acquisition

An employee at Paris-based Ipsen, Dishant Gupta, has been charged with insider trading. The Securities and Exchange Commission (SEC) accuse Gupta of profiting from non-public knowledge of Ipsen’s $247m buyout of cancer drug developer Epizyme. Gupta, who is based in the US, allegedly bought Epizyme shares ahead of the acquisition announcement in June 2022, before selling them all on the day for a profit of $260,078. In a separate court filing, Gupta has agreed to plead guilty to the charges.